脑啡肽酶及其抑制剂在心力衰竭治疗中的研究概述  

Research progress of neprilysin and its inhibitor in treatment of heart failure

作　　者：赵玲 马丹[1] 刘凤歧[1] ZHAO Ling;MA Dan;LIU Feng-Qi(Department of Critical Care Medicine, the First Hospital of Harbin Medical University, Harbin 150001, China)

机构地区：[1]哈尔滨医科大学附属第一医院内科危重症病房,哈尔滨150001

出　　处：《中华老年多器官疾病杂志》2022年第1期63-66,共4页Chinese Journal of Multiple Organ Diseases in the Elderly

基　　金：黑龙江省自然科学基金面上项目(H201446)。

摘　　要：脑啡肽酶(NEP)是一种普遍存在的金属肽酶,可以水解体内多种肽类物质。目前研究证明,NEP可以通过调节利钠肽系统、肾素-血管紧张素-醛固酮系统和激肽-激肽释放酶系统等影响心力衰竭进展,血管紧张素受体脑啡肽酶抑制剂在临床应用的益处也得到证实,因此NEP可以作为治疗心力衰竭的新靶点。然而也正因为NEP作用的广泛性,引发了人们对其在心力衰竭患者临床治疗安全性方面的普遍关注。Neprilysin(NEP)is a ubiquitous metallopeptidase that can hydrolyze a variety of peptides in the body.Current studies have shown that NEP can affect the progression of heart failure by regulating the natriuretic peptide system,renin-angiotensin-aldosterone system,and kinin-kallikrein system,etc.Because the benefits of angiotensin receptor neprilysin inhibitor has also been confirmed in clinical applications,NEP can be used as a new target for the treatment of heart failure.However,because of the wide application of NEP′s effects,it has aroused widespread concern about its safety in the clinical treatment of heart failure.

关 键 词：心力衰竭 脑啡肽酶 利钠肽 交感神经的过度激活 血管紧张素受体脑啡肽酶抑制剂 认知功能 

分 类 号：R541.6[医药卫生—心血管疾病]